Trials Annotator

Trial NCT00955305

Org. Study IDs: NCI-2011-01960
Secondary IDs: E3508 NCI-2011-01960 U10CA021115 U10CA180820

Last trial update was posted on 2018-06-06

MeSH Interventions

Bevacizumab Carboplatin Paclitaxel

MeSH Conditions

Adenocarcinoma of Lung Adenocarcinoma, Bronchiolo-Alveolar Carcinoma Carcinoma, Non-Small-Cell Lung Lung Neoplasms

Other Conditions

Bronchioloalveolar Lung Carcinoma Large Cell Lung Carcinoma Lung Adenocarcinoma Recurrent Non-Small Cell Lung Carcinoma Stage IV Non-Small Cell Lung Cancer

Stopping Reasons

The study was closed to accrual due to the end of the clinical development program with cixutumumab.

Limitations And Caveats

N/A

Result Publications

Argiris, A., Lee, J., Leach, J.W., Schiller, J.H.: Safety analysis of a phase II randomized trial of carboplatin (C), Paclitaxel (P), bevacizumab (B) with or without cixutumumab (CX) in patients (pts) with advanced non-squamous, non-small cell lung cancer (NSCLC). J Clin Oncol 2014;31(15s). Abstract e19018.

Annotations

Category Annotations

No annotators decided on categories yet

Intervention Annotations

#	Outdated	Intervention				Condition
#	Outdated	Name		Route	DrugBank ID	Condition